Publications in collaboration with researchers from Northwestern University (38)

2024

  1. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis

    Schizophrenia bulletin, Vol. 50, Núm. 3, pp. 496-512

  2. Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS

    Early Intervention in Psychiatry, Vol. 18, Núm. 4, pp. 255-272

  3. Multi-ancestry genome-wide association meta-analysis of Parkinson’s disease

    Nature Genetics, Vol. 56, Núm. 1, pp. 27-36

2023

  1. Author Correction: Elucidating causative gene variants in hereditary Parkinson’s disease in the Global Parkinson’s Genetics Program (GP2) (npj Parkinson's Disease, (2023), 9, 1, (100), 10.1038/s41531-023-00526-9)

    npj Parkinson's Disease

  2. Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2)

    npj Parkinson's Disease, Vol. 9, Núm. 1

  3. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

2022

  1. Altered succinylation of mitochondrial proteins, APP and tau in Alzheimer’s disease

    Nature Communications, Vol. 13, Núm. 1

2021

  1. Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit

    Schizophrenia Research, Vol. 227, pp. 10-17

  2. Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomes

    Neuropsychopharmacology, Vol. 46, Núm. 8, pp. 1468-1474

  3. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477

2019

  1. An injectable implant to stimulate the sphenopalatine ganglion for treatment of acute ischaemic stroke up to 24 h from onset (ImpACT-24B): an international, randomised, double-blind, sham-controlled, pivotal trial

    The Lancet, Vol. 394, Núm. 10194, pp. 219-229

  2. CD160 serves as a negative regulator of NKT cells in acute hepatic injury

    Nature Communications, Vol. 10, Núm. 1

  3. HVEM, a cosignaling molecular switch, and its interactions with BTLA, CD160 and LIGHT

    Cellular and Molecular Immunology, Vol. 16, Núm. 7, pp. 679-682

2018

  1. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

    The Lancet Oncology, Vol. 19, Núm. 9, pp. 1192-1204

2017

  1. Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma

    Hematological Oncology

2016

  1. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

2015

  1. Quest for missing proteins: Update 2015 on chromosome-centric human proteome project

    Journal of Proteome Research, Vol. 14, Núm. 9, pp. 3415-3431

  2. Use of ENCODE resources to characterize novel proteoforms and missing proteins in the human proteome

    Journal of Proteome Research, Vol. 14, Núm. 2, pp. 603-608

2014

  1. Clinical laboratory immunology: An indispensable player in laboratory medicine

    American Journal of Clinical Pathology, Vol. 142, Núm. 4, pp. 437-444

  2. Inaccuracy of haemoglobin A1c among HIV-infected men: Effects of CD4 cell count, antiretroviral therapies and haematological parameters

    Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 12, pp. 3360-3367